Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Protalix BioTherapeutics, Inc. (PLX) had Return on Equity of -11.41% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$9.12M |
|
$-5.50M |
|
$4.62M |
|
$4.50M |
|
$13.78M |
|
$-4.66M |
|
$-0.12M |
|
$-4.78M |
|
$-4.78M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-4.66M |
|
$-4.27M |
|
78.55M |
|
78.55M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$66.67M |
|
$4.88M |
|
$15.67M |
|
$82.35M |
|
$26.52M |
|
-- |
|
$7.60M |
|
$34.12M |
|
$48.23M |
|
$48.23M |
|
$48.23M |
|
80.43M |
|
| Cash Flow Statement Financials | |
$-11.99M |
|
$-2.37M |
|
$9.33M |
|
$19.76M |
|
$14.68M |
|
$-5.08M |
|
$2.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
49.36% |
|
-51.06% |
|
-51.06% |
|
-- |
|
-52.36% |
|
-60.34% |
|
$-13.63M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.18 |
|
1.03 |
|
87.22 |
|
|
Return on Equity |
-11.41% |
-11.41% |
|
-6.68% |
|
-11.41% |
|
$0.60 |
|
$-0.17 |
|
$-0.15 |
|